EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost‐utility analysis of sequential therapies for pediatric‐onset eosinophilic esophagitis

José Vicente Arcos-Machancoses iD, Elena Crehuá-Gaudiza iD, Cecilia Martínez-Costa iD

Journal of Pediatric Gastroenterology and Nutrition · 2025

DOI: 10.1002/jpn3.70106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von José Vicente Arcos-Machancoses und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Gastroenterology, Hepatology and Nutrition, Hospital Clínic Universitari, Valencia, Spain. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Cost-Benefit Analysis, Proton Pump Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Topical corticosteroids, proton‐pump inhibitors (PPI) and elimination diets (ED) are equally recommended as first‐line therapies for pediatric eosinophilic esophagitis (EoE). Dupilumab (DUP) is usually used for refractoriness. We aim to assess the cost‐utility of all potential sequential treatments for EoE.

Methods

A Markov model under the payer's perspective was used to describe induction, maintenance, and reinductions for nonresponders over 10 years. Dietary options included step‐up restriction starting from two foods, and from cow's milk (CM). Topical corticosteroids viscous solutions, or budesonide orodispersible tablets (BOT) were considered. Nonresponsiveness led to esophageal dilation. Simulation parameters were defined by systematic review. We deterministically selected the most cost‐effective permutation as reference. Incremental cost‐utility ratios (ICUR) of each alternative sequence were compared to a willingness‐to‐pay (WTP) threshold of €30,000. Sequences with the highest number of quality‐adjusted life‐years (QALY) and the highest QALY below WTP were probabilistically explored. Sensitivity analysis was performed.

Results

PPI‐ED(CM)‐BOT‐DUP was the most cost‐effective sequence, resulting in €2373/QALY and 7.20 QALY at the time horizon. DUP‐BOT‐PPI‐ED(CM) gave the uppermost QALY, 7.42, but any iteration was cost‐effective, yielding a median ICUR of €323,774/QALY. PPI‐BOT‐ED(CM)‐DUP, however, had a higher chance of being under the WTP (83%), showed a median ICUR of €25,156/QALY and provided 7.31 QALY. An 83% reduction of DUP price was needed to make DUP‐BOT‐PPI‐ED(CM) and PPI‐BOT‐ED(CM)‐DUP equally as efficient.

Conclusions

BOT and CM‐starting step‐up ED are present in both effective and cost‐effective sequential treatments for EoE. The option PPI‐BOT‐ED(CM)‐DUP succeeded in approaching the most effective alternative while balancing costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisCost-Benefit AnalysisProton Pump InhibitorsHumansChildQuality-Adjusted Life YearsMarkov ChainsAdrenal Cortex Hormones

Stichwörter der Autor:innen

acceptability curvecost‐effectivenessefficiencyquality of life

Substanzen

Proton Pump InhibitorsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Paediatric Gastroenterology, Hepatology and Nutrition, Hospital Clínic Universitari, Valencia, Spain.
  • INCLIVA Biomedical Research Institute, Valencia, Spain.
  • Universitat de València, Valencia, Spain.

ORCID-Profile: José Vicente Arcos-Machancoses, Elena Crehuá-Gaudiza, Cecilia Martínez-Costa

Förderung

  • None

Zitieren

APA

Arcos-Machancoses, J. V., Crehuá-Gaudiza, E., & Martínez-Costa, C. (2025). Cost‐utility analysis of sequential therapies for pediatric‐onset eosinophilic esophagitis. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70106

Vancouver

Arcos-Machancoses JV, Crehuá-Gaudiza E, Martínez-Costa C. Cost‐utility analysis of sequential therapies for pediatric‐onset eosinophilic esophagitis. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70106

BibTeX
@article{ArcosMachancoses2025,
  author = {Arcos-Machancoses, José Vicente and Crehuá-Gaudiza, Elena and Martínez-Costa, Cecilia},
  title = {Cost‐utility analysis of sequential therapies for pediatric‐onset eosinophilic esophagitis},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2025},
  doi = {10.1002/jpn3.70106}
}
Kostenlos starten →